Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target
The Pharma Data
JANUARY 4, 2021
Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T). PD-1 has always been a challenge for CAR-T development. “We believe Prof. About PD-1 Check-point inhibition.
40 
Let's personalize your content